If you have been reading about LC-MS/MS and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-11-29. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
== Comparison to SSRIs == As SNRIs were developed more recently than SSRIs, there are relatively few of them. However, the SNRIs are among the most widely used antidepressants today. In 2009, Cymbalta and Effexor were the 11th- and 12th-most-prescribed branded drugs in the United States, respectively. This translates to the 2nd- and 3rd-most-common antidepressants, behind Lexapro (escitalopram), an SSRI. In some studies, SNRIs demonstrated slightly higher antidepressant efficacy than the SSRIs (response rates 63.6% versus 59.3%). However, in one study escitalopram had a superior efficacy profile to venlafaxine. SSRIs do not significantly increase norepinephrine, which is where SNRIs may be used for a greater variety of conditions involving norepinephrine, such as chronic pain disorders. Some additional side effects noted with SNRIs can include increased heart rate and blood pressure. Overall, most patients are able to tolerate both similarly, and their choice depends more on their symptoms, medical history, and previous response to antidepressants.
=== Ulcerative colitis === Vedolizumab has been investigated in several studies in adult patients. Patients with moderate to severe active disease in whom conventional therapy or TNF-alpha antagonists were ineffective or could not be tolerated received either vedolizumab or placebo. The main measure of effectiveness was the proportion of patients whose symptoms improved after six weeks of treatment. Vedolizumab was shown to be more effective than placebo: 47% (106 out of 225) of patients who received vedolizumab showed an improvement in symptoms, compared with 26% (38 out of 149) of patients who received placebo. The study also showed that vedolizumab maintained the effect up to 52 weeks more effectively than placebo. Moreover, vedolizumab treatment was shown to achieve higher percentage of clinical remissions (31.3% vs. 22.5%) in patients with ulcerative colitis in comparison to adalimumab treatment.
=== Artificial limbs === NASA's continued funding, coupled with its collective innovations in robotics and shock-absorption/comfort materials are inspiring and enabling the private sector to create new and better solutions for animal and human prostheses. Advancements such as Environmental Robots Inc.'s development of artificial muscle systems with robotic sensing and actuation capabilities for use in NASA space robotic and extravehicular activities are being adapted in order to create more functionally dynamic artificial limbs. Additionally, other private-sector adaptations of NASA's memory foam technology have brought about custom-moldable materials offering the natural look and feel of flesh, as well as preventing friction between the skin and the prosthesis, and heat/moisture buildup.
=== Phytochemistry === Tulipanin is an anthocyanin found in tulips. It is the 3-rutinoside of delphinidin. Tuliposides and tulipalins can also be found in tulips and are responsible for allergies. Tulipalin A, or α-methylene-γ-butyrolactone, is a common allergen, generated by hydrolysis of the glucoside tuliposide A. It induces a dermatitis that is mostly occupational and affects tulip bulb sorters and florists who cut the stems and leaves. Tulipanin A and B are toxic to horses, cats and dogs.
Sources: en.wikipedia.org
== History == Tacrolimus was discovered in 1987 by a Japanese team led by pharmacologist Tohru Kino; it was among the first macrolide immunosuppressants discovered, preceded by the discovery of rapamycin (sirolimus) on Rapa Nui (Easter Island) in 1975. It is produced by a soil bacterium, Streptomyces tsukubensis. The name tacrolimus is derived from "Tsukuba macrolide immunosuppressant". The early development (investigational new drug phase) of tacrolimus, called at the time by the development code FK-506, happened in the next several years. A firsthand account of that process is given in Thomas Starzl's 1992 memoir. Tacrolimus was first approved by the US Food and Drug Administration (FDA) in 1994, for use in liver transplantation; the indications were extended to include kidney transplants. The first generic version of tacrolimus (capsule for oral route) was approved in the US in 2009. A generic version of tacrolimus for injection was approved in the US in 2017. Tacrolimus was approved for medical use in the European Union in 2002, for the treatment of moderate to severe atopic dermatitis. In 2007, the indications were expanded to include the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adults.
=== 1985 === February 6: The Reagan Doctrine commits the United States of America to supporting anti-Communist insurgencies in the Third World. March 10: General Secretary of the Communist Party of the Soviet Union Konstantin Chernenko dies. March 11: Mikhail Gorbachev becomes leader of the Soviet Union. March 15: Military rule ends in Brazil. March 24, 1985: Major Arthur D. Nicholson, a US Army Military Intelligence officer is shot to death by a Soviet sentry in East Germany. He is listed as the last US casualty in the Cold War. April 11: Enver Hoxha dies. Ramiz Alia takes over as First Secretary of the Party of Labor of Albania, becoming the de facto leader of Albania. April 22: The Trial of the Juntas convenes to prosecute the members of the National Reorganization Process (the military junta that governed Argentina from 1976 to 1983) for war crimes and crimes against humanity committed during its existence. May 20: John Anthony Walker is arrested by the FBI. August 6: Coinciding with the 40th anniversary of the atomic bombings of Hiroshima and Nagasaki, the Soviet Union begins what it has announced is a 5-month unilateral moratorium on the testing of nuclear weapons. The Reagan administration dismisses the dramatic move as nothing more than propaganda and refuses to follow suit. Gorbachev declares several extensions, but the United States fails to reciprocate, and the moratorium comes to an end on February 5, 1987. November 7: Crisis of Sigonella, diplomatic conflict between Italy and the United States.
The symbol of the registering organization (in the diagram above this is the US Government); the last two digits of the animal's year of birth (estimated from teeth), stacked vertically; the registration number, a unique sequence of angles arranged horizontally. The first two numerals of the registration number indicate the BLM facility at which the horse was processed (this is not always in the same state where the horse was captured). The next four numerals compose the horse's tag number and are randomly assigned during processing. Finally, a horizontal line beneath the registration number. This line acts as an orientation mark for the angle numerals. This is done in case the horse's skin shifts as it grows, if it loses weight or becomes cresty (an overabundance of fat deposition at the crest of the neck). Such distortions can appear to change one numeral into another. Angles are always interpreted with reference to the horizontal line. If a mustang has been offered for adoption three times and has not settled at any of its new locations the horse is referred to as "Sale Authority." This means that BLM is legally authorized to sell the horse to anyone willing to buy it. The BLM is prohibited by law from controlling wild horse populations through culling, but Sale Authority sometimes amounts to the same thing as intractable horses are often sold to slaughterhouses or their agents. Sale Authority is indicated with a large ᑌ shape after the registration number. If a horse is neither adopted nor deemed Sale Authority it is often housed at a long-term BLM pasture.
Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). Metabolic syndrome is associated with the risk of developing cardiovascular disease and type 2 diabetes. In the U.S., about 25% of the adult population has metabolic syndrome, a proportion increasing with age, particularly among racial and ethnic minorities. Insulin resistance, metabolic syndrome, and prediabetes are closely related to one another and have overlapping aspects. The syndrome is thought to be caused by an underlying disorder of energy utilization and storage, but the cause of the syndrome is an area of ongoing medical research. Researchers debate whether a diagnosis of metabolic syndrome implies differential treatment or increases risk of cardiovascular disease beyond what is suggested by the sum of its individual components.
== Development == The aldehyde tag is an artificial peptide tag recognized by the formylglycine-generating enzyme (FGE). Formylglycine is a glycine with a formyl group (-CHO) at the α-carbon. The sulfatase motif is the basis for the sequence of the peptide which results in the site-specific conversion of a cysteine to a formylglycine residue. The peptide tag was engineered after studies on FGE recognizable sequences in sulfatases from different organisms revealed a high homology in the sulfatase motif in bacteria, archaea as well as eukaryotes. Aldehydes and ketones are used as chemical reporters due to their electrophilic properties. These properties enable a reaction under mild conditions when using a strong nucleophilic coupling partner. Typically, hydrazides and aminooxy probes are used in bioconjugation by forming stabilized addition products with carbonyl groups that are favored under the physiological reaction conditions. At neutral pH, the equilibrium of Schiff base formation lies far to the reactant side. To form stable hydrazones and oximes, compound derivatives are used to yield more product. Since the pH optimum of 4 to 6 cannot be achieved by adding a catalyst due to associated toxicity, the reaction is slow in live cells. A typical reaction constant is 10−4 to 10−3 M−1 s−1. A carbonyl group is introduced into proteins as a chemical reporter using various techniques, including methods like stop codon suppression and aldehyde tagging. Limiting the use of aldehydes and ketones is their restricted bioorthogonality in certain cellular environments.
Sources: en.wikipedia.org
=== Risk modifiers === Environmental factors such as infections, geographic latitude, birth weight, antibiotic use, intestinal microbiota, socioeconomic status, hygiene, breastfeeding, and the timing of introduction of gluten into an infant's diet are theorised to contribute to the development of coeliac disease in genetically predisposed individuals. The consumption of gluten and timing of introduction, in a baby's life does not appear to increase the risk of coeliac disease, however in those who are genetically predisposed to coeliac disease, large amounts of gluten early in life may increase the risk of developing coeliac disease.
Cipepofol (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name), also known as ciprofol or by its developmental code name HSK3486, sold under the brand name Cypsedo, is a general anesthetic related to propofol which is used for anesthesia and sedation. The drug is used by intravenous infusion. A short-acting and highly selective GABAA positive allosteric modulator, ciprofol is 4 to 6 times more potent than other phenol derivatives such as propofol or fospropofol. In May 2026, cipepofol was approved for medical use in the United States. Manufactured by Haisco Pharmaceutical Group, ciprofol underwent phase I and II trials in Australia and China.
Oxytocin administered orally produces different effects on human behaviour and brain function than when given intranasally, possibly due to variations in the molecular transport and binding mechanisms.
interkinesis Also interphase II. The abbreviated pause in activities related to cell division that occurs during meiosis in some species, between the first and second meiotic divisions (i.e. meiosis I and meiosis II). No DNA replication occurs during interkinesis, unlike during the normal interphase that precedes meiosis I and mitosis.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.